targeting transglutaminase

is a clinical stage biotech company specialised in transglutaminase.

Zedira conducts its own development of small molecular drug candidates. In doing so, the company is working at the cutting edge of drug discovery involving small molecules that block dysregulated transglutaminases.

In addition, Zedira is a global brand for specialty reagents for research & development as well as diagnostics in the transglutaminase field. Numerous unique and high quality products help pushing forward transglutaminase-related science – both in academia and industry.

Zedira Managing Partners Hils Pasternack
Martin Hils and Ralf Pasternack,
managing partners of Zedira founded the company in 2007.

“Transglutaminase is our inspiration – improving health and creating value is our mission.“

Drug Development (clinical phase 2)
Zedira’s lead indication is celiac disease – a widespread disorder suffered by about 1% of the population and for which there is no therapeutic option available apart from a cumbersome and quality of life restricting gluten-free diet.
Inhibiting tissue transglutaminase (TG2) in the small intestinal mucosa with our drug candidate ZED1227 (first-in class) shall interrupt the mechanism of gluten intolerance in a targeted way. The compound is licensed to Dr. Falk Pharma for Europe. Dr. Falk Pharma took over responsibility for preclinical and clinical development as well as for approval and marketing of the drug.

Zedira now taps the potential of ZED1227 to address additional indications where dysregulated tissue transglutaminase (TG2) activity is targeted, especially fibrotic disorders (e.g. diabetic nephropathy).

Drug Discovery (lead optimization / drug candidates)
Using a rabbit animal model, Zedira showed the proof-of-principle of “safe” anticoagulation therapy by inhibition of blood plasma transglutaminase (Factor XIII, F13), which allows selective intervention in the coagulation cascade.
The crucial difference compared with the existing anticoagulants lies in the fact that a soft, easily degradable blood clot can still be formed while thrombin generation – and therefore thrombocyte function – is not affected.
A significant reduction in the life-threatening tendency to bleeding as provoked by current drugs is thus likely to be achieved. Today about 50% of patients are excluded from anticoagulation therapy due to the risk of bleeding events.
Therefore, an anticoagulant drug with a superior safety profile can look forward to a most attractive billion dollar market.

Specialist for Transglutaminase
has offered more than 200 specialty reagents for transglutaminase-related R&D for about 15 years.
Today, Zedira is the global brand for transglutaminase. Researchers from academia and industry (including 12 of the top 15 big pharma companies) benefit from Zedira’s cutting edge products – and in an increasing manner – from customised services.
Solutions for site specific labeling of proteins using transglutaminases form Zedira’s latest product field.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA